The Effect of Iron Deficiency Anemia During Pregnancy
Palabras clave
Abstracto
fechas
Verificado por última vez: | 02/28/2018 |
Primero enviado: | 10/26/2015 |
Inscripción estimada enviada: | 10/26/2015 |
Publicado por primera vez: | 10/27/2015 |
Última actualización enviada: | 03/16/2018 |
Última actualización publicada: | 03/19/2018 |
Fecha de inicio real del estudio: | 12/31/2015 |
Fecha estimada de finalización primaria: | 06/30/2017 |
Fecha estimada de finalización del estudio: | 11/30/2017 |
Condición o enfermedad
Intervención / tratamiento
Drug: Ferrous bis-glycinate group
Drug: Ferrous glycine sulphate group
Fase
Grupos de brazos
Brazo | Intervención / tratamiento |
---|---|
Active Comparator: Ferrous bis-glycinate group The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks. | Drug: Ferrous bis-glycinate group |
Active Comparator: Ferrous glycine sulphate group The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks. | Drug: Ferrous glycine sulphate group |
Criterio de elegibilidad
Edades elegibles para estudiar | 20 Years A 20 Years |
Sexos elegibles para estudiar | Female |
Acepta voluntarios saludables | si |
Criterios | Inclusion Criteria: 1. Singleton pregnancy. 2. Gestational age 14-18 weeks. 3. Mild to moderate anemia 4. No associated medical or obstetric complications. 5. Women not already receiving iron therapy. 6. Women accepted to participate in the study. Exclusion Criteria: 1. Multiple pregnancy 2. Severe anemia 3. Iron hypersensitivity. 4. Liver diseases. 5. Women refuse to participate in the study. |
Salir
Medidas de resultado primarias
1. the rate of increase of Hemoglobin level [8 weeks]